Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart disease is uncertain. METHODS: We conducted a population-based case-control study of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in 2168 women who underwent radiotherapy for breast cancer between 1958 and 2001 in Sweden and Denmark; the study included 963 women with major coronary events and 1205 controls. Individual patient information was obtained from hospital records. For each woman, the mean radiation doses to the whole heart and to the left anterior descending coronary artery were estimated from her radiotherapy chart. RESULTS: The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy. The proportional increase in the rate of major coronary events per gray was similar in women with and women without cardiac risk factors at the time of radiotherapy. CONCLUSIONS: Exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease. The increase is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years. Women with preexisting cardiac risk factors have greater absolute increases in risk from radiotherapy than other women. (Funded by Cancer Research UK and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent evidence shows risk at lower doses (<0.5 Gy), with an estimated latency of 10 years or more29–31.”
From Red risks for a journey to the red planet: The highest priority human health risks for a mission to Mars (2020) · cites this paper as [29]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
(2011) · The Lancet · doi:10.1016/s0140-6736(11)61629-2 · Cited by 3,937
Self-citationCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
The completeness of the Swedish Cancer Register – a sample survey for year 1998
Barlow, L., Westergren, K., Holmberg, L., & Talbäck, M. (2009) · Acta Oncologica · doi:10.1080/02841860802247664 · Cited by 1,236
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Self-citationDarby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70251-5 · Cited by 1,049
Self-citationLifetime risks of cardiovascular disease
Berry, J. D., Dyer, A., Cai, X., Garside, D. B., Ning, H., Thomas, A., Greenland, P., Van Horn, L., Tracy, R. P., & Lloyd-Jones, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1012848 · Cited by 945
Cuzick, J., Stewart, H., Rutqvist, L., Houghton, J., Edwards, R., Redmond, C., Peto, R., Baum, M., Fisher, B., & Host, H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.447 · Cited by 889
Self-citation
Research works printed but not linked: 1
- Jones B, 2001, Clin Oncol (R Coll Radiol), 13, 71
Cited by
Items 701–800 of 1,001
Milano, M. T., Strawderman, R. L., Venigalla, S., Ng, K., & Travis, L. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000213 · Cited by 38
“Radiotherapy for BC is associated with excess heart disease,(50) with a significant dose-response relationship reported in a European study of women treated with older technologies (1958–2001) and resultant larger radiation dose-volume cardiac exposure.(51) Although the relative number of CVD deaths in our more contem…”
BackgroundEnvironmental carcinogens and mutational pathways in atherosclerosis
Pulliero, A., Godschalk, R., Andreassi, M. G., Curfs, D. M. J., van Schooten, F., & Izzotti, A. (2015) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2015.01.007 · Cited by 41
Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line
Gu, X., Li, J.-Y., Guo, J., Li, P.-S., & Zhang, W.-H. (2015) · Medical Science Monitor · doi:10.12659/msm.894475 · Cited by 36
Tran, V., Zablotska, L. B., Brenner, A. V., & Little, M. P. (2017) · Scientific Reports · doi:10.1038/srep44147 · Cited by 39
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 57
A cost-effective technique for cardiac sparing with deep inspiration-breath hold (DIBH)
Macrie, B. D., Donnelly, E. D., Hayes, J. P., Gopalakrishnan, M., Philip, R., Reczek, J., Prescott, A. E., & Strauss, J. B. (2015) · Physica Medica · doi:10.1016/j.ejmp.2015.06.006 · Cited by 37
The future of nanosized radiation enhancers
Pottier, A., Borghi, E., & Lévy, L. (2015) · British Journal of Radiology · doi:10.1259/bjr.20150171 · Cited by 37
“Thus, a radiotherapy technique involving the use of nanosized radiation enhancers could allow for a radiation dose reduction to the heart while maintaining the radiation dose to the breast and therefore improve the therapeutic ratio.(12) To realize such ambition, proof of enhanced treatment efficacy should first be ac…”
MethodTakahashi, N., Misumi, M., Murakami, H., Niwa, Y., Ohishi, W., Inaba, T., Nagamachi, A., & Suzuki, G. (2020) · Journal of Radiation Research · doi:10.1093/jrr/rraa050 · Cited by 36
Duma, M. N., Herr, A.-C., Borm, K. J., Trott, K. R., Molls, M., Oechsner, M., & Combs, S. E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00130 · Cited by 36
“(3) analyzed the risk of ischemic heart disease in women after radiotherapy for breast cancer.”
BackgroundSchöllnberger, H., Eidemüller, M., Cullings, H. M., Simonetto, C., Neff, F., & Kaiser, J. C. (2017) · Radiation and Environmental Biophysics · doi:10.1007/s00411-017-0722-5 · Cited by 36
“Such evidence stems from analyzing cohorts of radiotherapy patients (Darby et al. 2013) and animal experiments (Stewart et al.”
BackgroundAbouegylah, M. L., Braunstein, L. Z., El‐Din, M. A. A., Niemierko, A., Salama, L., Elebrashi, M., Edgington, S. K., Remillard, K. A., Napolitano, B. N., Naoum, G. E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5053-y · Cited by 36
Loap, P., Tkatchenko, N., Nicolas, E., Fourquet, A., & Kirova, Y. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.09.044 · Cited by 36
Wang, X., Palaskas, N. L., Hobbs, B. P., Abe, J., Nead, K. T., Yusuf, S. W., Hermann, J., Deswal, A. M., & Lin, S. H. (2022) · Cancers · doi:10.3390/cancers14051304 · Cited by 38
“Typically, the heart as a whole is considered as an organ at risk during thoracic RT, and the mean heart dose (MHD) has generally been used to assess the risk of coronary events in previous studies [4,14].”
BackgroundMethodBreast cancer radiation therapy: A bibliometric analysis of the scientific literature
Franco, P., Felice, F. D., Jagsi, R., Marta, G. N., Kaidar‐Person, O., Gabryś, D., Kim, K., Ramiah, D., Meattini, I., & Poortmans, P. M. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.11.015 · Cited by 38
Jacobs, J. E. J., L’Hoyes, W., Lauwens, L., Yu, Y., Brusselmans, M., Weltens, C. G., Voigt, J., Wildiers, H. P. M. W., Neven, P., Herrmann, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027855 · Cited by 38
Role of DNA Damage in Cardiovascular Disease
Ishida, T., Ishida, M., Tashiro, S., Yoshizumi, M., & Kihara, Y. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1194 · Cited by 38
Gabani, P., Patel, H., Thomas, M. A., Bottani, B., Goddu, S. M., Straube, W. L., Margenthaler, J. A., Ochoa, L. L., Bradley, J. D., & Zoberi, I. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.09.005 · Cited by 36
“While surgery plus RT is effective for local recurrence, recent research has shown increased late toxicities including cardiotoxicity as a result of re-irradiation [7,8].”
BackgroundHolst‐Hansson, A. (2018) · doi:10.24834/2043/25059 · Cited by 42
Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients
Al-Droubi, S. S., Jahangir, E., Kochendorfer, K. M., Krive, M., Laufer‐Perl, M., Gilon, D., Okwuosa, T. M., Gans, C. P., Arnold, J. H., Bhaskar, S., et al. (2023) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztad031 · Cited by 35
Tramm, T., Kyndi, M., Myhre, S., Nord, S., Alsner, J., Sørensen, F. B., Sørlie, T., & Overgaard, J. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.925580 · Cited by 35
“The risk-estimation does, however, not suffi ciently refl ect the heterogeneity in breast cancer, and some patients may not benefi t from PMRT but are only risking side effects [2,3].”
BackgroundRespiratory gating for proton beam scanning versus photon 3D-CRT for breast cancer radiotherapy
Flejmer, A., Edvardsson, A., Dohlmar, F., Josefsson, D., Nilsson, M., Nyström, P. W., & Daşu, A. (2016) · Acta Oncologica · doi:10.3109/0284186x.2015.1120883 · Cited by 35
“Treatments plans were compared in terms of OAR radiation burden using dosimetric parameters representative for international recommendations or for radiobiological models [2,3].”
BackgroundMethodHigh-dose Radiation Induced Heart Damage in a Rat Model.
Kiscsatári, L., Sárközy, M., Kovari, B. P., Varga, Z., Gömöri, K., Morvay, N., Leprán, I., Hegyesi, H., Fábián, G., Cserni, B., et al. (2016) · PubMed · Cited by 35
Mohamad, O., Shiao, J., Zhao, B., Roach, K., Ramirez, E., Vo, D. T., Thomas, K. M., Gu, X., Spangler, A. E., Albuquerque, K., et al. (2017) · Practical Radiation Oncology · doi:10.1016/j.prro.2017.04.006 · Cited by 35
Filippi, A. R., Meregalli, S., Russo, A. D., Levis, M., Ciammella, P., Buglione, M., Guerini, A. E., Marco, G. D., Sanctis, V. D., Vagge, S., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01504-8 · Cited by 35
Chung, R., Tyebally, S. M., Chen, D. H., Kapil, V., Walker, J. M., Addison, D., Ismail-Khan, R. R., Guha, A., & Ghosh, A. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103346 · Cited by 40
“iotherapy to the abdominal viscera confers both prognostic and disease control in colorectal and gynecological malignancy There are known long term sequelae of head and neck radiotherapy including secondary malignancy, autonomic dysfunction, early cardiac valve fibrosis and accelerated coronary artery atherosclerosis…”
BackgroundNaimi, Z., Moujahed, R., Néji, H., Yahyaoui, J., Hamdoun, A., Bohli, M., & Kochbati, L. (2021) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2020.09.003 · Cited by 35
Martín‐Garcia, A., Mitroi, C. D., Mazón‐Ramos, P., García‐Sánz, R., Virizuela, J. A., Arenas, M., Cabello, I. E., Albert, D. C., Sánchez, M. A., Arrarte, V., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.11.014 · Cited by 37
Or, M., Liu, B., Lam, J., Vinod, S. K., Xuan, W., Yeghiaian‐Alvandi, R., & Hau, E. K. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-85131-7 · Cited by 40
Breast Cancer and the Cardiovascular Disease: A Narrative Review
Cherukuri, S. P., Chikatimalla, R., Dasaradhan, T., Koneti, J., Gadde, S., & Kalluru, R. (2022) · Cureus · doi:10.7759/cureus.27917 · Cited by 42
Approach and Management of Breast Cancer in the Elderly
Karuturi, M. S., VanderWalde, N. A., & Muss, H. B. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.011 · Cited by 40
Radiation dose distribution in functional heart regions from tangential breast cancer radiotherapy
Wollschläger, D., Karle, H., Stockinger, M., Bartkowiak, D., Bührdel, S., Merzenich, H., Wiegel, T., Blettner, M., & Schmidberger, H. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.01.020 · Cited by 39
Hernandez, M., Zhang, R., Sanders, M. E., & Newhauser, W. D. (2016) · Journal of Proton Therapy · doi:10.14319/jpt.11.9 · Cited by 35
Parikh, R. R., Rhome, R. M., Hug, E. B., Tsai, H. K., Cahlon, O., Chon, B. H., & Goenka, A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.019 · Cited by 35
Improving the efficiency of breast radiotherapy treatment planning using a semi‐automated approach
Mitchell, A., Wai, P., Colgan, R. M., Kirby, A. M., & Donovan, E. M. (2016) · Journal of Applied Clinical Medical Physics · doi:10.1002/acm2.12006 · Cited by 35
“In the context of the planning study, the lack of statistically significant changes in mean dose to the heart for the original and scripted plans is beneficial given that the Darby study showed a linear relationship between mean heart dose and the risk of a major cardiac event.(21) One limitation of the script is in c…”
MethodEvolution of radiotherapy techniques in breast conservation treatment
Boyages, J., & Baker, L. (2018) · Gland Surgery · doi:10.21037/gs.2018.11.10 · Cited by 40
“5% or 5 per 1,000 by age 80, irrespective of age at the time of treatment (91).”
BackgroundRadiotherapy-induced heart disease: a review of the literature
Zou, B., Schuster, J. P., Niu, K., Huang, Q., Rühle, A., & Huber, P. E. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz025 · Cited by 36
“For example, ischemic heart disease has become the most common reason for cardiac death in cancer patients after thoracic radiotherapy.(11) A retrospective analysis involving 2168 breast cancer patients who received radiotherapy showed a linear correlation between radiation dose and coronary artery changes, showing th…”
BackgroundTudda, A., Donzelli, E., Nicolini, G., Semperboni, S., Bossi, M., Cavaletti, G., Castriconi, R., Mangili, P., Vecchio, A. D., Sarno, A., et al. (2022) · Medical Physics · doi:10.1002/mp.15348 · Cited by 34
Brunt, A. M., Haviland, J., Wheatley, D. A., Sydenham, M. A., Bloomfield, D. J., Chan, C., Cleator, S. J., Coles, C. E., Donovan, E. M., Fleming, H., et al. (2023) · Health Technology Assessment · doi:10.3310/wwbf1044 · Cited by 35
Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment
Lorenzo-Esteller, L., Ramos-Polo, R., Riverola, A. P., Morillas, H., Berdejo, J., Pernas, S., Pomares, H., Asiáin, L., Garay, A., Pérez, E. M., et al. (2024) · Cancers · doi:10.3390/cancers16203466 · Cited by 34
“Typically, radiation doses at the cardiac level are V5Gy < 55 Gy; V10Gy < 33%; V20Gy < 10%; and V40Gy < 5% with a mean dose <4 Gy [20,21].”
BackgroundFiorentino, A., Mazzola, R., Ricchetti, F., Giaj‐Levra, N., Fersino, S., Naccarato, S., Sicignano, G., Ruggieri, R., Paola, G. D., Massocco, A., et al. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.02.013 · Cited by 34
The Influence of C-Ions and X-rays on Human Umbilical Vein Endothelial Cells
Helm, A., Lee, R., Durante, M., & Ritter, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00005 · Cited by 35
“, breast cancer or Hodgkin lymphoma (1, 2, 30).”
Tangent-based volumetric modulated arc therapy for advanced left breast cancer
Yu, P., Wu, C., Nien, H., Lui, L. T., Shaw, S., & Tsai, Y. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1167-y · Cited by 34
“4% per gray (Gy) with no apparent threshold [5].”
BackgroundBiological Cardiac Tissue Effects of High-Energy Heavy Ions – Investigation for Myocardial Ablation
Rapp, F., Simoniello, P., Wiedemann, J., Bahrami, K., Grünebaum, V., Ktitareva, S., Durante, M., Lugenbiel, P., Thomas, D., Lehmann, H. I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41314-x · Cited by 34
Skyttä, T., TUOHINEN, S. S., Luukkaala, T. H., Virtanen, V., Raatikainen, P. M. J., & Kellokumpu‐Lehtinen, P. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1630751 · Cited by 35
“The risk of radiation-induced heart disease (RIHD) is shown to be dose-dependent [8,9].”
BackgroundBurrage, M. K., & Ferreira, V. M. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-165 · Cited by 37
“4% per Gray mean dose to the heart), particularly in those with pre-existing cardiac risk factors or ischaemic heart disease (84).”
BackgroundHoeller, U., Borgmann, K., Oertel, M., Haverkamp, U., Budach, V., & Eich, H. T. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0024 · Cited by 34
Isikawa, M. M., & Guidelli, É. J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c20689 · Cited by 34
Radiation-induced coronary artery disease: a difficult clinical conundrum
Kirresh, A. Z., White, L. J., Mitchell, A., Ahmad, S., Obika, B. D., Davis, S., Ahmad, M., & Candilio, L. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0600 · Cited by 37
Should breathing adapted radiotherapy also be applied for right-sided breast irradiation?
Essers, M., Poortmans, P. M., Verschueren, K. M. S., Hol, S., & Cobben, D. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1102321 · Cited by 34
“4% per Gy with no apparent threshold [4].”
BackgroundRadiation-Induced Cardiovascular Disease
Mousavi, N., & Nohria, A. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0259-0 · Cited by 37
Shin, S. M., No, H. J., Vega, R. B. M., Fenton-Kerimian, M., Maisonet, O. G., Hitchen, C. J., DeWyngaert, J. K., & Formenti, S. C. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.10.022 · Cited by 37
Radiation Toxicity to the Cardiovascular System
Marmagkiolis, K., Finch, W., Tsitlakidou, D., Josephs, T., Iliescu, C., Best, J. F., & Yang, E. H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0502-4 · Cited by 37
“4 % per 1 Gy of mean radiation dose received by the heart in patients treated between 1958 and 2001 [40].”
BackgroundHeart Transplantation Outcomes in Radiation-Induced Restrictive Cardiomyopathy
Al-Kindi, S. G., & Oliveira, G. H. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.03.014 · Cited by 34
Darapu, A., Balakrishnan, R., Sebastian, P., Hussain, M. R. K., Ravindran, P., & John, S. (2017) · Case Reports in Oncology · doi:10.1159/000453607 · Cited by 34
Walker, V., Crijns, A. P. G., Langendijk, J. A., Spoor, D. S., Vliegenthart, R., Combs, S. E., Mayinger, M. C., Eraso, A., Guedea, F., Fiúza, M., et al. (2018) · JMIR Research Protocols · doi:10.2196/resprot.9906 · Cited by 35
“In parallel with the increase in the incidence of BC, the prevalence of BC survivors at risk for cardiac complications will, thus, gradually increase [3,4,6-8].”
BackgroundInfluentialLi, J., Sudiwala, S., Berthoin, L., Mohabbat, S., Gaylord, E. A., Sinada, H., Cruz‐Pacheco, N., Chang, J. C., Jeon, O., Lombaert, I. M. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc8753 · Cited by 35
Left-Sided Whole Breast Irradiation with Hybrid-IMRT and Helical Tomotherapy Dosimetric Comparison
Shiau, A., Hsieh, C.-H., Tien, H., Yeh, H.-P., Lin, C.-T., Shueng, P., & Wu, L.-J. (2014) · BioMed Research International · doi:10.1155/2014/741326 · Cited by 33
“,myocardial infraction, coronary revascularization, or death from ischemic heart disease) increased linearly with the mean dose to the heart, with no apparent threshold [6].”
BackgroundProton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment
Zeng, C., Plastaras, J. P., James, P., Tochner, Z. A., Hill‐Kayser, C. E., Hahn, S. M., & Both, S. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1191665 · Cited by 33
López‐Fernández, T., & Thavendiranathan, P. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.12.027 · Cited by 37
Koivumäki, T. M., Fogliata, A., Zeverino, M., Boman, E. L., Sierpowska, J., Moeckli, R., Vallet, V., Cozzi, L., Heikkilä, J., Väänänen, A., et al. (2017) · Physica Medica · doi:10.1016/j.ejmp.2017.12.009 · Cited by 33
Leger, K. J., Baker, K. S., Cushing‐Haugen, K. L., Flowers, M. E. D., Leisenring, W. M., Martin, P. J., Mendoza, J. A., Reding, K. W., Syrjala, K. L., Lee, S. J., et al. (2018) · Cancer · doi:10.1002/cncr.31227 · Cited by 33
Zhang, W., Haylock, R., Gillies, M., & Hunter, N. (2019) · Journal of Radiological Protection · doi:10.1088/1361-6498/ab02b2 · Cited by 36
Radioprotective Effect of Hesperidin: A Systematic Review
Musa, A. E., Omyan, G., Esmaely, F., & Shabeeb, D. (2019) · Medicina · doi:10.3390/medicina55070370 · Cited by 37
“The functionalities of coronary vessels, valves, the pericardium, and the myocardium are adversely affected after irradiation [52].”
BackgroundHotca, A. E., Thor, M., Deasy, J. O., & Rimner, A. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.09.003 · Cited by 41
“In general, radiation-induced cardiac toxicity has been considered a late effect as observed from breast cancer data [14,15] and Hodgkin’s lymphoma data [16,17], but there are a”
BackgroundCardiovascular Toxicities of Radiation Therapy
Lewis, G. D., & FARACH, A. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-4-274 · Cited by 40
Joseph, K. J., Vos, L. J., Gabos, Z., Pervez, N., Chafe, S., Tankel, K., Warkentin, H., Ghosh, S., Amanie, J., Powell, K., et al. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.07.005 · Cited by 33
Heart dose linked with cardiac events and overall survival in lung cancer radiotherapy
Pan, L., Lei, D., Wang, W., Luo, Y., & Wang, D. (2020) · Medicine · doi:10.1097/md.0000000000021964 · Cited by 33
Connor, A. E., Schmaltz, C., Jackson‐Thompson, J., & Visvanathan, K. (2021) · Cancer · doi:10.1002/cncr.33530 · Cited by 33
“27 The risk of postdiagnostic cardiac events may be intensified among women who have coexisting CVD at diagnosis because of cardiotoxicity resulting from certain cancer treatments.(19,23,25,26) The biologic mechanisms that contribute to cardiac toxicity could provide some explanation for the increase in risk of CVD de…”
BackgroundFranceschini, D., Fogliata, A., Spoto, R., Dominici, L., Faro, L. L., Franzese, C., Comito, T., Lobefalo, F., Reggiori, G., Cozzi, L., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.09.006 · Cited by 33
The Lymphatic System in Breast Cancer: Anatomical and Molecular Approaches
Natale, G., Stouthandel, M. E. J., Hoof, T. V., & Bocci, G. (2021) · Medicina · doi:10.3390/medicina57111272 · Cited by 35
“On the one hand, a more accurate radiation treatment could increase treatment efficacy and prevent long term side effects such as heart disease or secondary lung cancer [68,69].”
BackgroundTrends in heart disease mortality among breast cancer survivors in the US, 1975–2017
Vo, J. B., Ramin, C. A., Barac, A., de González, A. B., & Veiga, L. H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06515-5 · Cited by 33
“Though we observed declining heart disease SMRs among breast cancer survivors treated with radiotherapy, it is important not to lose sight of this progress, as the association of heart disease still exists with radiotherapy use [8].”
BackgroundChazova, I. E., Ageev, F. T., Владимировна, А. А., Vicenya, M. V. V., Gilyarov, M. Y., Martynyuk, T. V., Панченко, Е. П., Poltavskaya, M. G., Potievskaya, V. I., Trofimova, O. P., et al. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-6-79 · Cited by 36
Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies
Shamseddine, A. A., Patel, S. H., Chavez, V. A., Moore, Z., Adnan, M., Bona, M. D., Li, J., Dang, C. T., Ramanathan, L. V., Oeffinger, K. C., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220809 · Cited by 33
Zhou, B., Wang, Z., Dou, Q., Li, W., Li, Y., Yan, Z., Sun, P., Zhao, B., Li, X., Shen, F., et al. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0112 · Cited by 38
BRCA1/2 mutation carriers are potentially at higher cardiovascular risk
Jong, M. A.-D., Maas, A. H. E. M., Massuger, L. F. A. G., Hoogerbrugge, N., & de Hullu, J. A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.008 · Cited by 37
“Women with preexising CVD risk factors have greater absolute increases in risk rom radiotherapy than other women [138].”
BackgroundTucker, S. L., Liao, Z. X., Dinh, J., Bian, S. X., Mohan, R., Martel, M. K., & Grosshans, D. R. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.831185 · Cited by 33
Zhang, L., Zhou, Z., Mei, X., Yang, Z., Ma, J., Chen, X., Wang, J., Liu, G., Yu, X., & Guo, X. (2015) · Medicine · doi:10.1097/md.0000000000001143 · Cited by 40
Treatment Planning Considerations for Robotic Guided Cardiac Radiosurgery for Atrial Fibrillation
Blanck, O., Ipsen, S., Chan, M. K. H., Bauer, R., Kerl, J. M., Hunold, P., Jacobi, V., Bruder, R., Schweikard, A., Rades, D., et al. (2016) · Cureus · doi:10.7759/cureus.705 · Cited by 33
Potential Morbidity Reduction With Proton Radiation Therapy for Breast Cancer
Braunstein, L. Z., & Cahlon, O. (2018) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.11.009 · Cited by 33
Cardiac Function After Radiation Therapy for Breast Cancer
van den Bogaard, V. A. B., van Luijk, P., Hummel, Y. M., van der Meer, P., Schuit, E., Boerman, L. M., Maass, S. W. M. C., Nauta, J. F., Steggink, L. C., Gietema, J. A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.02.003 · Cited by 33
Tjessem, K. H., Bosse, G., Fosså, K., Reinertsen, K. V., Fosså, S. D., Johansen, S., & Fosså, A. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.01.006 · Cited by 36
“Some studies have shown that cardiovascular late effects may not develop until two decades after treatment [5,14].”
BackgroundResultInfluentialHeart Disease Mortality in Cancer Survivors: A Population‐Based Study in Japan
Gon, Y., Zha, L., Sasaki, T., Morishima, T., Ohno, Y., Mochizuki, H., Sobue, T., & Miyashiro, I. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029967 · Cited by 32
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer
Ioffe, D., Bhatia-Patel, S., Gandhi, S., Hamad, E. A., & Dotan, E. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.02.001 · Cited by 38
Kirby, A. M., Finneran, L., Griffin, C. L., Brunt, A. M., Cafferty, F. H., Alhasso, A. A., Chan, C., Haviland, J., Jefford, M. L., Sawyer, E. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00194-9 · Cited by 32
Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer
Plastaras, J. P., Berman, A. T., & Freedman, G. M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.10.001 · Cited by 32
Nolan, M. T., Russell, D., & Marwick, T. H. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.12.020 · Cited by 36
“increase in major coronary events per Gy over 5 decades (5).”
BackgroundInter-observer variation in delineating the coronary arteries as organs at risk
Wennstig, A.-K., Garmo, H., Hållström, P., Nyström, P. W., Edlund, P., BLOMQVIST, C. P., Sund, M., & Nilsson, G. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.11.007 · Cited by 32
“However, in a recent large population based study from Scandinavia, a statistical model including doses to the LAD in addition to the whole heart, failed to improve the association between radiation doses and the risk of coronary events [6].”
BackgroundLuo, J., Jin, K., Chen, X., Wang, X., Yang, Z., Zhang, L., Mei, X., Ma, J., Zhang, X., Zhou, Z., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.11.003 · Cited by 35
The Two-way Relationship Between Cancer and Atherosclerosis
Raposeiras‐Roubín, S., & Cordero, A. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.12.010 · Cited by 40
Ramadan, R., Vromans, E., Anang, D. C., Decrock, E., Mysara, M., Monsieurs, P., Baatout, S., Leybaert, L., & Aerts, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39317-9 · Cited by 33
Barjaktarović, Ž., Merl‐Pham, J., Braga-Tanaka, I., Tanaka, S., Hauck, S. M., Saran, A., Mancuso, M., Atkinson, M. J., Tapio, S., & Azimzadeh, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205239 · Cited by 34
Guha, A., Dey, A. K., Arora, S., Cavender, M. A., Vavalle, J. P., Sabik, J. F., Jiménez, E., Jneid, H. M., & Addison, D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014248 · Cited by 32
“This is important, given the expected continued increase in patients with cancer presenting with significant AS. Valvular disease has been long acknowledged as a serious adverse effect of cancer therapy caused by the effects of exposure to radiotherapy and chemotherapy.4,28 Radiation therapy is associated with heighte…”
BackgroundInfluentialSong, J., Tang, T., Caudrelier, J.-M., Bélec, J., Chan, J., Lacasse, P., Aldosary, G., & Nair, V. J. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.09.019 · Cited by 32
Ko, H., Chang, J. S., Moon, J. Y., Lee, W. H., Shah, C., Shim, J. S., Han, M. C., Baek, J. G., Park, R. H., Kim, Y. B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645328 · Cited by 32
“4% per 1-Gy increase in the mean heart dose (MHD) (6).”
BackgroundThe role of connexin proteins and their channels in radiation-induced atherosclerosis
Ramadan, R., Baatout, S., Aerts, A., & Leybaert, L. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03716-3 · Cited by 34
“Abscopal effects may in principle be clinically useful to extend the radiation effects to tumor cells outside the radiation field [81] but they may as well be harmful when reaching distant healthy cells and tissues [5], effectively restricting their application.”
BackgroundPasquier, D., Bataille, B., Tinier, F. L., Bennadji, R., Langin, H., Escande, A., Tresch, E., Darloy, F., Carlier, D., Crop, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83159-3 · Cited by 36
Lai, Y., Chen, H. H. W., & Tsai, Y. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01936-w · Cited by 32
“Most studies take the MHD as a surrogate parameter in evaluating radiation-associated cardiac toxicity, but whether this parameter can reflect the real condition of coronary arteries remains uncertain.”
BackgroundInfluentialKim, J. S., Choi, S. W., Park, Y., Kim, S. J., Choi, C. H., Cha, M., & Chang, J. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010351 · Cited by 32
“High-dose irradiation to the heart during thoracic radiotherapy for lymphoma, breast, lung, or esophageal cancer is known to be related to late cardiac toxicity [43,44]; however, the cardiac toxicity could be observed months or years after irradiation.”
BackgroundMutter, R. W., Giri, S. J., Fruth, B. F., Remmes, N. B., Boughey, J. C., Harless, C. A., Ruddy, K. J., McGee, L. A., Afzal, A., Gao, R. W., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00388-1 · Cited by 32
Unhealthy diets: a common soil for the association of metabolic syndrome and cancer
Esposito, K., Ciardiello, F., & Giugliano, D. (2014) · Endocrine · doi:10.1007/s12020-013-0151-4 · Cited by 35
“Several groups of cancer survivors are considered to be at increased risk of the metabolic syndrome, owing to prolonged survival (metabolic syndrome increases with age), raised prevalence of its components after hormone-modifying therapy (androgen suppression or antiestrogen therapy, for prostate cancer or breast canc…”
Background
Metadata
- Authors
- Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., Jensen, M.-B., Nisbet, A., Peto, R., Rahimi, K., Taylor, C., & Hall, P.
- Affiliations
- University of Oxford (GB)
- University of Southern Denmark (DK)
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Aalborg University Hospital (DK)
- University of South Florida (US)
- Danderyds sjukhus (SE)
- Rigshospitalet (DK)
- Royal Surrey County Hospital (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-14
- Volume
- 368
- Issue
- 11
- Pages
- 987-998
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2154375587
- Cited by
- 3,974
- References
- 38
- Citations by year
- 2026: 277 · 2025: 290 · 2024: 270 · 2023: 358 · 2022: 359 · 2021: 392 · 2020: 344 · 2019: 285 · 2018: 278 · 2017: 268 · 2016: 285 · 2015: 259 · 2014: 195 · 2013: 107
- FWCI
- 191.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Cancer Research UK
- National Institute for Health and Care Research (RRX 108)
- British Heart Foundation (RE/08/004, CRE RE/08/004)
- University of Oxford (RE/08/004)
- European Commission
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- breast cancer radiotherapy, ischemic heart disease, coronary events, myocardial infarction, coronary revascularization, radiation-induced heart disease, left anterior descending artery, radiation dose, cardiovascular risk factors, women
- MeSH terms
- Adult, Aged, Breast Neoplasms, Female, Heart, Humans, Mastectomy, Middle Aged, Radiation Injuries, Radiotherapy Dosage, Risk, Risk Factors, Case-Control Studies, Chemotherapy, Adjuvant, Myocardial Ischemia, Radiotherapy, Adjuvant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.